Minerva Neurosciences, Inc. (NASDAQ:NERV) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Minerva Neurosciences, Inc. (NASDAQ:NERV) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers

Story continues below

(b) Resignation of Director

On January31, 2018, Marc Beer notified the Board of Directors (the “Board”) of Minerva Neurosciences, Inc. (the “Company”) of his intention to resign as a member of the Board, effective upon the close of business on January31, 2018, including from his role as Chairman of the Board and Chairman of the Compensation Committee. Mr.Beer is resigning to focus on other opportunities and his decision did not involve any disagreement with the Company, its management or the Board.

On February5, 2018, the Company issued a press release announcing the resignation of Mr.Beer and the appointment of Dr.Rémy Luthringer as Executive Chairman of the Board and William Doyle as Lead Independent Director.A copy of the press release is filed herewith as Exhibit99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 5.02. Financial Statements and Exhibits
Exhibit No.

Description

99.1 Press Release, dated February5, 2018.


Minerva Neurosciences, Inc. Exhibit
EX-99.1 2 d526629dex991.htm EX-99.1 EX-99.1 Exhibit 99.1     Contact:     William B. Boni   VP,…
To view the full exhibit click here

About Minerva Neurosciences, Inc. (NASDAQ:NERV)

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company’s product portfolio include MIN-101 for the treatment of schizophrenia; MIN-117 for the treatment of major depressive disorder (MDD); MIN-202 (also known as JNJ-42847922) for the treatment of insomnia disorder and adjunctive MDD, and MIN-301 for the treatment of Parkinson’s disease. MIN-101 blocks serotonin receptors and sigma receptors, over two receptors in the brain that are involved in the regulation of mood, cognition, sleep and anxiety. MIN-117 is meant to block a specific subtype of serotonin receptor called 5-HT1A. MIN-202 is a selective orexin 2 receptor antagonist it is developing in collaboration with Janssen Pharmaceutica NV. MIN-301 is a soluble recombinant form of the Neuregulin-1b1 protein.

An ad to help with our costs